Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 33 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR EMA Recommends Extension of Indications for Daratumumab June 10, 2021 Patient Guide on Cancer Pain Management Now Available Also in French December 16, 2025 Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... December 11, 2021 Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence... February 29, 2024 Load more HOT NEWS Could Bacteria Help Find Cancer? Giving Birth Before Age 20 Cuts Breast Risk By 50%, And... 5 Ways Teens or Young Adults Can Cope With Loneliness During... Charity promotes eco-fashion with collection at Love Not Landfill pop-up
